CD226 and Miyoshi myopathy: The expression of these and other activating (e.g., DNAM-1) or inhibitory (e.g., KIR, NKG2A) receptors on NK cells, as well as their ligands on MM cells, may also be altered in MM patients, and vary significantly from patient to patient [9,23,27].